OncBioMune Submits Documents to Commercialize Norepinefrine in Mexico

OncBioMune Pharmaceuticals (OTCQB:OBMP) announced it has submitted documents for the official transfer of the Mexican rights to market Norepinefrine in the country.
As quoted in the press release:

On June 19, 2017, the Company announced acquiring the sanitary registration and intellectual property rights to Norepinefrine in Mexico and other markets from the Mexican subsidiary of the world’s biggest generic drug company.
Norepinefrine is approved in Mexico as indicated for the treatment of low blood pressure and heart failure. The Norepinefrine registration can also be used in other Central and Latin American countries. OncBioMune continues to conduct its due diligence on the most attractive markets, with plans to selectively launch the drug in other markets in the future.
OncBioMune is presently negotiating details to bring Norepinefrine manufacturing to a state-of-the-art facility in Latin America, a move that will contain costs and provide the Company greater control in the supply chain.

Click here to read the full press release.

Source: www.marketwired.com